Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer

Ilan G. Ron, Tal H. Vishne, Natalie Kraminsky, Amiram Bar-Am, Moshe J. Inbar

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

A phase II study of carboplatin and etoposide as salvage polychemotherapy in metastatic, infiltrating breast carcinoma was carried out with 25 multiply pretreated patients. Six of 25 patients (24%) had a partial response that lasted an average of 3.5 months; of the six responders, four had undergone either four or five previous chemotherapeutic treatments. Eight of 25 patients (32%) had stable disease, and 11 (44%) manifested disease progression. The median survival from time of entry to the salvage protocol was 8 months. There were treatment responses in lung, chest wall, liver, and skeleton. The most common side effects were leukopenia (68% of 25 patients), thrombocytopenia (56%), anemia (40%), fever (28%), and weakness (16%). Carboplatin combined with etoposide may be an effective and tolerable salvage regimen in advanced breast cancer.

Original languageEnglish
Pages (from-to)35-37
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number1
DOIs
StatePublished - Feb 1999
Externally publishedYes

Keywords

  • Carboplatin
  • Etoposide
  • Metastatic breast cancer
  • Salvage therapy

Fingerprint

Dive into the research topics of 'Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer'. Together they form a unique fingerprint.

Cite this